{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T14:53:55Z","timestamp":1648911235748},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmaceutical Association (1996)"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1331\/108658002763316897","type":"journal-article","created":{"date-parts":[[2003,6,17]],"date-time":"2003-06-17T16:53:18Z","timestamp":1055868798000},"page":"460-468","source":"Crossref","is-referenced-by-count":0,"title":["Dyspepsia: Initial Evaluation and Treatment"],"prefix":"10.1016","volume":"42","author":[{"given":"Brian L.","family":"Erstad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1331\/108658002763316897_bb0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1056\/NEJM199811053391907","article-title":"Management of nonulcer dyspepsia.","volume":"339","author":"Fisher","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0015","first-page":"159","article-title":"Identification of subgroups of functional bowel disorders.","volume":"3","author":"Drossman","year":"1990","journal-title":"Gastroenterology."},{"key":"10.1331\/108658002763316897_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(98)70542-6","article-title":"AGA technical review: evaluation of dyspepsia.","volume":"114","author":"Talley","year":"1998","journal-title":"Gastroenterology."},{"key":"10.1331\/108658002763316897_bb0025","first-page":"1773","article-title":"Evaluation and management of dyspepsia.","volume":"60","author":"Bazaldua","year":"1999","journal-title":"Am Earn Physician."},{"key":"10.1331\/108658002763316897_bb0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5107(81)73156-0","article-title":"The national ASGE survey on upper GI bleeding.","volume":"27","author":"Silverstein","year":"1981","journal-title":"Gastrointest Endosc."},{"key":"10.1331\/108658002763316897_bb0035","series-title":"Clinical Practice of Gastroenterology.","first-page":"21","article-title":"Gastroesophageal reflux disease","author":"Sontag","year":"1999"},{"key":"10.1331\/108658002763316897_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0149-2918(00)90002-X","article-title":"Pharmacologic strategies for treating gastroesophageal reflux disease.","volume":"22","author":"Vivian","year":"2000","journal-title":"Clin Ther."},{"key":"10.1331\/108658002763316897_bb0045","series-title":"Acute Care of the Abdomen.","first-page":"136","article-title":"GI drugs","author":"Spirt","year":"1998"},{"key":"10.1331\/108658002763316897_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0016-5085(98)70541-4","volume":"114","author":"American Gastroenterological Association medical position statement: evaluation of dyspepsia","year":"1998","journal-title":"Gastroenterology."},{"key":"10.1331\/108658002763316897_bb0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0016-5107(81)73155-9","article-title":"The national ASGE survey on upper GI bleeding.","volume":"27","author":"Silverstein","year":"1981","journal-title":"Gastrointest Endosc."},{"key":"10.1331\/108658002763316897_bb0060","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJM199409153311107","article-title":"Bleeding peptic ulcer.","volume":"331","author":"Laine","year":"1994","journal-title":"New Engl J Med."},{"key":"10.1331\/108658002763316897_bb0065","series-title":"Clinical Practice of Gastroenterology.","first-page":"273","article-title":"Duodenal ulcer","author":"Stefan","year":"1999"},{"key":"10.1331\/108658002763316897_bb0070","series-title":"Clinical Practice of Gastroenterology.","first-page":"264","article-title":"Gastric ulcer","author":"Faigel","year":"1999"},{"key":"10.1331\/108658002763316897_bb0075","series-title":"Clinical Practice of Gastroenterology.","first-page":"249","article-title":"Helicobacter pylori: epidemiology and pathogenesis","author":"Cave","year":"1999"},{"key":"10.1331\/108658002763316897_bb0080","series-title":"Clinical Practice of Gastroenterology.","first-page":"255","article-title":"Helicobacter pylori: diagnostic testing and treatment","author":"Cutler","year":"1999"},{"key":"10.1331\/108658002763316897_bb0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(00)02553-8","article-title":"Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial","volume":"356","author":"Lassen","year":"2000","journal-title":"Lancet."},{"key":"10.1331\/108658002763316897_bb0090","first-page":"1691","article-title":"The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori.","volume":"95","author":"Vakil","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"10.1331\/108658002763316897_bb0095","first-page":"924","article-title":"The American College of Gastroenterology bleeding registry: preliminary findings.","volume":"92","author":"Peura","year":"1997","journal-title":"Am J Gastroenterol."},{"issue":"suppl 51","key":"10.1331\/108658002763316897_bb0100","first-page":"8","article-title":"NSAID-induced GI complications: The ARAMIS perspective\u20141997.","volume":"25","author":"Singh","year":"1998","journal-title":"J Rheumatol."},{"key":"10.1331\/108658002763316897_bb0105","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"GI toxicity with celecoxib or nonsteroidal anti-inflammatory drugs for osteoarthritis or rheumatoid arthritis: the CLASS study.","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA."},{"key":"10.1331\/108658002763316897_bb0110","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper GI toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0115","series-title":"Dear healthcare provider letter: important correction of drug information","author":"Fort","year":"2001"},{"key":"10.1331\/108658002763316897_bb0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1023\/A:1018880818217","article-title":"Association of nonsteroidal anti-inflammatory drugs with outcome in upper and lower GI bleeding.","volume":"42","author":"Wilcox","year":"1997","journal-title":"Digest Dis Sci."},{"key":"10.1331\/108658002763316897_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM198307073090105","article-title":"Association of adrenocorticosteroid therapy and peptic-ulcer disease.","volume":"209","author":"Messer","year":"1983","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/bmj.2.6081.237","article-title":"Clinical findings, early endoscopy, and multivariate analysis in patients bleeding from the upper GI tract.","volume":"2","author":"Morgan","year":"1977","journal-title":"BMJ."},{"key":"10.1331\/108658002763316897_bb0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-114-9-735","article-title":"Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs.","volume":"114","author":"Piper","year":"1991","journal-title":"Ann Intern Med."},{"key":"10.1331\/108658002763316897_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.272.1.65","article-title":"NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease","volume":"272","year":"1994","journal-title":"JAMA."},{"key":"10.1331\/108658002763316897_bb0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1086-5802(16)31036-1","article-title":"Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.","volume":"40","author":"Welage","year":"2000","journal-title":"J Am Pharm Assoc."},{"key":"10.1331\/108658002763316897_bb0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/archinte.158.8.842","article-title":"Treatment of Helicobacter pylori infection","volume":"158","author":"Salcedo","year":"1998","journal-title":"Arch Intern Med."},{"key":"10.1331\/108658002763316897_bb0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ajhp\/58.4.331","article-title":"ASHP therapeutic position statement of the identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults","volume":"58","year":"2001","journal-title":"Am J Health Syst Pharm."},{"key":"10.1331\/108658002763316897_bb0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs.","volume":"338","author":"Hawkey","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0165","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","article-title":"Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.","volume":"334","author":"Taha","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0170","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to the nonsteroidal anti-inflammatory drug use in the high-risk patient.","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology."},{"key":"10.1331\/108658002763316897_bb0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1345\/aph.19300","article-title":"The effect of Helicobacter pylori eradication on NSAID-induced GI toxicity","volume":"35","author":"Kanji","year":"2001","journal-title":"Ann Pharmacother."},{"key":"10.1331\/108658002763316897_bb0180","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","article-title":"Preventing recurrent upper GI bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen","volume":"344","author":"Chan","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0185","first-page":"1","article-title":"Drugs for the treatment of peptic ulcer","volume":"39","year":"1997","journal-title":"The Medical Letter."},{"key":"10.1331\/108658002763316897_bb0190","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/j.1572-0241.1998.00684.x","article-title":"Guidelines for the management of Helicobacter pylori infection","volume":"93","author":"Howden","year":"1998","journal-title":"Am J Gastroenterol."},{"key":"10.1331\/108658002763316897_bb0195","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinte.160.9.1285","article-title":"Helicobacter pylori","volume":"160","author":"Peterson","year":"2000","journal-title":"Arch Intern Med."},{"issue":"suppl","key":"10.1331\/108658002763316897_bb0200","first-page":"S6","article-title":"Beyond heartburn: extraesophageal manifestations of gastroesophageal reflux disease.","volume":"7","author":"Richter","year":"2001","journal-title":"Am J Manag Care."},{"key":"10.1331\/108658002763316897_bb0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-133-3-200008010-00007","article-title":"Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma.","volume":"133","author":"Lagergren","year":"2000","journal-title":"Ann Intern Med."},{"key":"10.1331\/108658002763316897_bb0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/gut.47.3.444","article-title":"Quality of life measurement in GI and liver disorders","volume":"47","author":"Borgaonkar","year":"2000","journal-title":"Gut"},{"key":"10.1331\/108658002763316897_bb0215","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM199903183401101","article-title":"Symptomatic gastroesophageal reflux as a risk factor for esophageal carcinoma.","volume":"340","author":"Lagergren","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0220","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.285.18.2331","article-title":"Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease.","volume":"285","author":"Spechler","year":"2001","journal-title":"JAMA."},{"key":"10.1331\/108658002763316897_bb0225","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0149-2918(00)83061-1","article-title":"Clinical experience with pantoprazole in gastroesophageal reflux disease.","volume":"22","author":"Avner","year":"2000","journal-title":"Clin Ther."},{"key":"10.1331\/108658002763316897_bb0230","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000016970","article-title":"Pathophysiology and pharmacological treatment of gastroesophageal reflux disease.","volume":"18","author":"Storr","year":"2000","journal-title":"Dig Dis."},{"key":"10.1331\/108658002763316897_bb0235","first-page":"295","article-title":"Helicobacter pylori: beyond peptic ulcer disease","volume":"5","author":"Wisniewski","year":"1997","journal-title":"Gastroenterologist."},{"key":"10.1331\/108658002763316897_bb0240","series-title":"Acid Related Diseases: Biology and Treatment.","first-page":"253","article-title":"Dyspepsia","author":"Modlin","year":"1998"},{"key":"10.1331\/108658002763316897_bb0245","first-page":"8","article-title":"Current European concepts in the management of Helicobacter pylori infection","volume":"41","author":"The European Helicobacter Pylori Study Group","year":"1991","journal-title":"The Maastricht Consensus Report. Gut."},{"issue":"suppl 1","key":"10.1331\/108658002763316897_bb0250","first-page":"29","article-title":"Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine, or ranitidine.","volume":"4","author":"Nwokolo","year":"1990","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1331\/108658002763316897_bb0255","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1046\/j.1365-2036.1999.00584.x","article-title":"Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998.","volume":"13","author":"Talley","year":"1999","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1331\/108658002763316897_bb0260","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJM199812243392602","article-title":"Lack of effect of treating","volume":"339","author":"Blum","year":"1998","journal-title":"N Engl J Med. Helicobacter pylori"},{"key":"10.1331\/108658002763316897_bb0265","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/bmj.318.7187.833","article-title":"Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months\u2019 follow up","volume":"318","author":"Talley","year":"1999","journal-title":"BMJ."},{"key":"10.1331\/108658002763316897_bb0270","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199910073411502","article-title":"Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia","volume":"341","author":"Talley","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-134-5-200103060-00008","article-title":"Therapy for Helicobacter pylori in patients with nonulcer dyspepsia","volume":"134","author":"Laine","year":"2001","journal-title":"Ann Intern Med."},{"key":"10.1331\/108658002763316897_bb0280","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199812243392601","article-title":"Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia","volume":"339","author":"McColl","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316897_bb0285","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/bmj.321.7262.659","article-title":"Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia","volume":"321","author":"Moayyedi","year":"2000","journal-title":"BMJ."},{"key":"10.1331\/108658002763316897_bb0290","series-title":"Clinical Practice of Gastroenterology.","first-page":"226","article-title":"Dyspepsia","author":"Metz","year":"1999"}],"container-title":["Journal of the American Pharmaceutical Association (1996)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215302643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215302643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T21:23:00Z","timestamp":1584825780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1086580215302643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S1086580215302643"],"URL":"https:\/\/doi.org\/10.1331\/108658002763316897","relation":{},"ISSN":["1086-5802"],"issn-type":[{"value":"1086-5802","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}